LY503430 is a AMPA receptor potentiator. LY503430 has both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP. It is orally bioavailable and the main application it is currently being developed for is treatment of Parkinson's Disease. References: Duthion B, Gomez Pardo D, Cossy J. Enantioselective synthesis of β-fluoroamines from β-amino alcohols: application to the synthesis of LY503430. Org Lett. 2010 Oct 15;12(20):4620-3. doi: 10.1021/ol1019579. PubMed PMID: 20849096.

纯度：≥98%

CAS：625820-83-9